DeepMed Research

Erlotinib

Generic Name: Erlotinib

Brand Names: Tarceva

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃N_₃O_₄

CAS Number: 183321-74-6

Unique Ingredient Identifier: J4T82NDH7E

Background: Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

Indication: Erlotinib is indicated for:

The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.

Associated Conditions: Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer

Clinical Trials

Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

Phase 2

Conditions: Biliary Tract Cancer

Interventions: Drug: Pemetrexed 500 MG
Drug: Erlotinib

First Posted Date: 2017-04-12

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 44

Registration Number: NCT03110484

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy

Phase 2

Completed

Conditions: Colo-rectal Cancer

Interventions: Drug: Pemetrexed
Drug: Tarceva 100Mg Tablet

First Posted Date: 2017-03-22

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 29

Registration Number: NCT03086538

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Phase 1

Completed

Conditions: Lung Cancer
Recurrent Lung Adenocarcinoma
Lung Adenocarcinoma
Lung Cancer Metastatic
Lung Cancer Stage IV
Recurrent Lung Cancer

Interventions: Drug: Trametinib
Drug: Erlotinib

First Posted Date: 2017-03-10

Last Posted Date: 2024-04-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 24

Registration Number: NCT03076164

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC

Phase 2

Conditions: Epidermal Growth Factor Receptor
Non-small Cell Lung Cancer

Interventions: Drug: Erlotinib Hydrochloride

First Posted Date: 2017-03-09

Last Posted Date: 2017-03-09

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 90

Registration Number: NCT03074864

Locations: 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China

Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC

Phase 1

Terminated

Conditions: Lung Cancer, Nonsmall Cell

Interventions: Drug: IRX4204
Drug: erlotinib

First Posted Date: 2016-12-13

Last Posted Date: 2025-05-14

Lead Sponsor: Io Therapeutics

Target Recruit Count: 12

Registration Number: NCT02991651

Locations: 🇺🇸
Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, United States

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

Phase 2

Completed

Conditions: Familial Adenomatous Polyposis
Attenuated Familial Adenomatous Polyposis

Interventions: Drug: Erlotinib
Drug: Erlotinib Hydrochloride

First Posted Date: 2016-11-11

Last Posted Date: 2022-07-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT02961374

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇵🇷
University of Puerto Rico, San Juan, Puerto Rico
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States

and more 5 locations

Study of Ixazomib and Erlotinib in Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Ixazomib
Drug: Erlotinib

First Posted Date: 2016-10-21

Last Posted Date: 2023-04-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 9

Registration Number: NCT02942095

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Phase 2

Terminated

Conditions: Stage IV Squamous Cell Lung Carcinoma AJCC v7
Recurrent Squamous Cell Lung Carcinoma
MET Positive

Interventions: Drug: Erlotinib Hydrochloride
Other: Laboratory Biomarker Analysis
Biological: Rilotumumab

First Posted Date: 2016-10-06

Last Posted Date: 2020-03-19

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 9

Registration Number: NCT02926638

Locations: 🇺🇸
Grant Medical Center, Columbus, Ohio, United States
🇺🇸
MedStar Union Memorial Hospital, Baltimore, Maryland, United States
🇺🇸
Sky Ridge Medical Center, Lone Tree, Colorado, United States

and more 617 locations

The Drug Rediscovery Protocol (DRUP Trial)

First Posted Date: 2016-10-05

Last Posted Date: 2024-01-24

Lead Sponsor: The Netherlands Cancer Institute

Target Recruit Count: 1550

Registration Number: NCT02925234

Locations: 🇳🇱
Meander medisch centrum, Amersfoort, Netherlands
🇳🇱
Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱
Amsterdam UMC, locatie AMC, Amsterdam, Netherlands

and more 33 locations

Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma

Phase 3

Completed

Conditions: Cancer

Interventions: Drug: YiQiFang
Drug: placebo granules
Drug: Erlotinib®
Drug: YangYinFang
Drug: Gefitinib®
Drug: YiQiYangYinFang
Drug: Icotinib®

First Posted Date: 2016-09-05

Last Posted Date: 2019-04-11

Lead Sponsor: Shanghai University of Traditional Chinese Medicine

Target Recruit Count: 23

Registration Number: NCT02889692

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy